GC Genome Corporation (KOSDAQ:340450)

GC Genome Revenue

GC Genome had revenue of 8.29B KRW in the quarter ending June 30, 2026, with 6.17% growth. This brings the company's total for the last twelve months to 32.64B, up 13.71% year-over-year. In the year 2025, GC Genome had annual revenue of 31.53B with 21.81% growth. That makes GC Genome the 32,553rd largest company in the world by revenue and 2,073rd in South Korea.

• Revenue (ttm): 32.64B
• Revenue Growth: +13.71%
• P/S Ratio: 6.22
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 202.92B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

• Cancer Test 10.20B 39.4%
• Obstetrics and Gynecology 6.53B 25.2%
• Rare Genetic Disease 4.89B 18.9%
• Checkup 4.26B 16.4%
• Other 24.00M 0.1%

By Geography

• South Korea 25.12B 97.0%
• Overseas 767.00M 3.0%

Fiscal year ended Dec 31, 2024 See the full GC Genome breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	31.53B	5.65B	21.81%
Dec 31, 2024	25.89B	-1.40B	-5.15%
Dec 31, 2023	27.29B	3.18B	13.18%
Dec 31, 2022	24.11B	5.62B	30.36%
Dec 31, 2021	18.50B	4.94B	36.46%

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error